Publicacións nas que colabora con Rosario García de Vicuña (21)

2024

  1. Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting

    Vaccines, Vol. 12, Núm. 6

2023

  1. Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain

    Frontiers in Immunology, Vol. 14

  2. Immunoglobulins in systemic sclerosis management. A large multicenter experience

    Autoimmunity Reviews, Vol. 22, Núm. 11

2021

  1. Treatment with tofacitinib in refractory psoriatic arthritis: A national multicenter study of the first 87 patients in clinical practice

    Journal of Rheumatology, Vol. 48, Núm. 10, pp. 1552-1558

2019

  1. Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit

    Reumatologia Clinica, Vol. 15, Núm. 2, pp. 63-68

2018

  1. Primary respiratory disease in patients with systemic lupus erythematosus: Data from the Spanish rheumatology society lupus registry (RELESSER) cohort

    Arthritis Research and Therapy, Vol. 20, Núm. 1

2017

  1. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): Results of a multicentre, dose escalation, randomised, singleblind, placebo-controlled phase Ib/IIa clinical trial

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 196-202

  2. Recommendations by the Spanish Society of Rheumatology for the management of patients diagnosed with rheumatoid arthritis who cannot be treated with methotrexate

    Reumatologia Clinica, Vol. 13, Núm. 3, pp. 127-138

2016

  1. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review

    Rheumatology International, Vol. 36, Núm. 8, pp. 1043-1063

2015

  1. Erratum to "Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project" [Semin Arthritis Rheum 44 (2015) 618-626]

    Seminars in Arthritis and Rheumatism

  2. Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study

    Rheumatology International, Vol. 35, Núm. 9, pp. 1525-1534

  3. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis

    Rheumatology (United Kingdom), Vol. 54, Núm. 7, pp. 1200-1209

2014

  1. Estándares de calidad en una Unidad de Hospitalización de Día reumatológica. Propuesta del Grupo de Trabajo de Hospitales de Día de la Sociedad Española de Reumatología

    Reumatologia Clinica, Vol. 10, Núm. 6, pp. 380-388

  2. The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: Results from a nationwide cohort in Spain (LESIMAB)

    Lupus, Vol. 23, Núm. 10, pp. 1014-1022

2012

  1. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study

    Lupus, Vol. 21, Núm. 10, pp. 1063-1076

2011

  1. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas

    Reumatologia Clinica, Vol. 7, Núm. 5, pp. 284-298

2010

  1. Influence of gender on treatment response in a cohort of patients with early rheumatoid arthritis in the area 2 of Madrid

    Reumatologia Clinica, Vol. 6, Núm. 3, pp. 134-140

  2. Recommendations for the management of influenza A (H1N1) in rheumatic patients with immunosuppression

    Reumatologia Clinica, Vol. 6, Núm. 1, pp. 63-68

2008

  1. Are the C-reactive protein values and erythrocyte sedimentation rate equivalent when estimating the 28-joint disease activity score in rheumatoid arthritis?

    Clinical and Experimental Rheumatology, Vol. 26, Núm. 5, pp. 769-775

2007

  1. Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): Informe de la situación, 26 de enero de 2006

    Reumatologia Clinica, Vol. 3, Núm. 1, pp. 4-20